Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 13/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652926 | 0.94 | FGFR1 (0.49) | FGFR1HPGDMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2653242 | 0.93 | MAPK1 (0.48) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL2652290 | 0.91 | FGFR1 (0.46) | FGFR1HPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2653608 | 0.90 | FGFR1 (0.48) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL2651819 | 0.88 | HPGD (0.55) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL2654310 | 0.88 | FGFR1 (0.52) | FGFR1HPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2653221 | 0.87 | FGFR1 (0.46) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL2651651 | 0.87 | FGFR1 (0.48) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL4704314 | 0.87 | FGFR1 (0.51) | FGFR1HPGDKMT2AMEN1MAPK1 | |
| SCHEMBL2661194 | 0.87 | FGFR1 (0.51) | FGFR1HPGDKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615896-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2008-04-23 | — | — | EP | claimed |
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUSEARCH A/S (DK) | 2006-10-26 | — | — | US | claimed |
| EP-1615896-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2008-04-23 | — | — | EP | disclosed |
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUSEARCH A/S (DK) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA2, GABRA1, GABRA5 | FGFR1 2849/4885HPGD 1091/4885KMT2A 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.